Jm Kaplan

Summary

Affiliation: Genzyme Corporation
Country: USA

Publications

  1. ncbi request reprint Solid-phase epitope recovery: a high throughput method for antigen identification and epitope optimization
    Carla A Lawendowski
    Genzyme Molecular Oncology, Framingham, MA 01701, USA
    J Immunol 169:2414-21. 2002
  2. ncbi request reprint Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells
    William M Siders
    Genzyme Molecular Oncology, 31 New York Ave, Framingham, Massachusetts 01701, USA
    Mol Ther 7:498-505. 2003
  3. ncbi request reprint Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes
    Michael A Perricone
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    J Immunother 27:273-81. 2004
  4. ncbi request reprint New cancer vaccine approaches
    Johanne M Kaplan
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Drugs Today (Barc) 40:913-29. 2004
  5. ncbi request reprint Adenovirus-based cancer gene therapy
    Johanne M Kaplan
    Genzyme Corporation, 5 Mountain Road, Framingham, MA 01701 9322, USA
    Curr Gene Ther 5:595-605. 2005
  6. ncbi request reprint Immunomodulatory activity of mesenchymal stem cells
    Johanne M Kaplan
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
    Curr Stem Cell Res Ther 6:297-316. 2011
  7. doi request reprint Therapeutic benefit of treatment with anti-thymocyte globulin and latent TGF-beta1 in the MRL/lpr lupus mouse model
    Jm Kaplan
    Immunotherapy Research Department, Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Lupus 17:822-31. 2008
  8. doi request reprint Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies
    Cheryl A Guyre
    Genzyme Corporation, P O Box 9322, Framingham, MA 01701, USA
    J Immunol Methods 333:51-60. 2008
  9. pmc Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
    YanPing Hu
    Genzyme Corporation, Framingham, MA 01701, USA
    Immunology 128:260-70. 2009
  10. doi request reprint Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models
    William M Siders
    Genzyme Corporation, Framingham, MA 010701, USA
    Leuk Lymphoma 51:1293-304. 2010

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Solid-phase epitope recovery: a high throughput method for antigen identification and epitope optimization
    Carla A Lawendowski
    Genzyme Molecular Oncology, Framingham, MA 01701, USA
    J Immunol 169:2414-21. 2002
    ..These data provide a rationale for the design of superior vaccines comprising a mixture of structurally diverse yet functionally convergent peptides...
  2. ncbi request reprint Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells
    William M Siders
    Genzyme Molecular Oncology, 31 New York Ave, Framingham, Massachusetts 01701, USA
    Mol Ther 7:498-505. 2003
    ....
  3. ncbi request reprint Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes
    Michael A Perricone
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    J Immunother 27:273-81. 2004
    ....
  4. ncbi request reprint New cancer vaccine approaches
    Johanne M Kaplan
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Drugs Today (Barc) 40:913-29. 2004
    ..Recent progress in immunology and tumor biology has allowed for the development of new vaccination strategies and approaches to enhance clinical efficacy...
  5. ncbi request reprint Adenovirus-based cancer gene therapy
    Johanne M Kaplan
    Genzyme Corporation, 5 Mountain Road, Framingham, MA 01701 9322, USA
    Curr Gene Ther 5:595-605. 2005
    ..A review of various Ad-based cancer gene therapy approaches and recent progress in the area are presented herein...
  6. ncbi request reprint Immunomodulatory activity of mesenchymal stem cells
    Johanne M Kaplan
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
    Curr Stem Cell Res Ther 6:297-316. 2011
    ..The immunomodulatory properties, mechanism of action and potential clinical utility of MSCs are reviewed herein...
  7. doi request reprint Therapeutic benefit of treatment with anti-thymocyte globulin and latent TGF-beta1 in the MRL/lpr lupus mouse model
    Jm Kaplan
    Immunotherapy Research Department, Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Lupus 17:822-31. 2008
    ..The mechanism of action did not involve suppression of autoantibody formation but may involve the activity of CD4+CD25+FoxP3+ Tregs, which were found to be induced by ATG + TGF-beta1 treatment in vitro...
  8. doi request reprint Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies
    Cheryl A Guyre
    Genzyme Corporation, P O Box 9322, Framingham, MA 01701, USA
    J Immunol Methods 333:51-60. 2008
    ..This report demonstrates the feasibility and utility of a powerful method for the rapid evaluation in vivo of therapeutic antibody candidates for cancer...
  9. pmc Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
    YanPing Hu
    Genzyme Corporation, Framingham, MA 01701, USA
    Immunology 128:260-70. 2009
    ..The hCD52 transgenic mouse appears to be a useful model and has provided evidence for the previously uncharacterized involvement of neutrophils in the activity of alemtuzumab...
  10. doi request reprint Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models
    William M Siders
    Genzyme Corporation, Framingham, MA 010701, USA
    Leuk Lymphoma 51:1293-304. 2010
    ....
  11. doi request reprint Induction of antitumor immunity by semi-allogeneic and fully allogeneic electrofusion products of tumor cells and dendritic cells
    William M Siders
    Genzyme Corporation, 49 New York Avenue, Framingham, Massachusetts, USA
    Clin Transl Sci 2:75-9. 2009
    ..This previously undescribed activity of a fully allogeneic fusion product introduces the possibility of using defined allogeneic tumor and DC lines to simplify vaccine manufacturing...
  12. ncbi request reprint Tumor treatment with complexes of cationic lipid and noncoding plasmid DNA results in the induction of cytotoxic T cells and systemic tumor elimination
    William M Siders
    Genzyme Molecular Oncology, Framingham, Massachusetts 01701, USA
    Mol Ther 6:519-27. 2002
    ..p. Treatment with lipid/pNull complex, therefore, represents an attractive immune-based treatment modality that could potentially be applied to many tumor types...